ライフサイエンスコーパス: estriol

1 We could detect less than 400 pg of estriol.

2 2 weeks with either bevacizumab 1% (4 mg/d), estriol 0.1% (0.4 mg/d), tranexamic acid 10% (40 mg/d),

3 86 ng/L for 17beta-estradiol, 0.030 ng/L for estriol, 0.049 ng/L for 17alpha-ethinylestradiol, and 0.

4 ed for the separation of estrone, estradiol, estriol, 16-epiestriol, 17-epiestriol, 16-ketoestradiol,

5 hydroxy, and 2- and 4-methoxy derivates, and estriol, 16-epiestriol, 17-epiestriol, and 16-ketoestrad

6 triol-17beta(beta-D-glucuronide) (E317G) and estriol-16(beta-D-glucuronide) (E316G), inhibited MDR1-m

7 ydroxy and 2- and 4-methoxy derivatives; and estriol, 17-epiestriol, 16-ketoestradiol, and 16-epiestr

8 ed for study were estrone, 17beta-estradiol, estriol, 17alpha-ethinylestradiol, and equilin.

9 tes of the estrogen D-ring (100 micromol/L), estriol-17beta(beta-D-glucuronide) (E317G) and estriol-1

10 lpha-fetoprotein, 4 percent for unconjugated estriol, 29 percent for hCG, 25 percent for the free bet

11 tes in the human, estrone 3-sulfate (E1-3S), estriol 3-sulfate (E3-3S), and 17 beta-estradiol 3-sulfa

12 m permuted block design to either daily oral estriol (8 mg) or placebo, each in combination with inje

13 lapsing remitting patients treated with oral estriol (8 mg/day) demonstrated significant decreases in

14 iol-17beta and two of its other metabolites, estriol and 2-methoxyestriol (< or =10 microM), did not

15 Estriol and 4-hydroxyestradiol were found to reduce Ba2+

16 were 500-fold slower than agonists (such as estriol and beta-estradiol).

17 The estrogenic ligands estriol and tamoxifen were also effective at raising syn

18 Among steroid hormones, estriol and testosterone were significantly positively a

19 f natural estrogens (estrone, estradiol, and estriol) and overall SSF performance for drinking water

20 roidal estrogens (17beta-estradiol, estrone, estriol, and 17alpha-estradiol) were tested in these ass

21 ncluding four estrogens (estrone, estradiol, estriol, and ethinylestradiol), eight perfluoroalkyl car

22 l human chorionic gonadotropin, unconjugated estriol, and inhibin A at 15 through 18 weeks of gestati

23 s, estrogens (estrone, 17beta-estradiol, and estriol), androgens (androstenedione, androsterone, tran

24 ng flavoprotein reductase A (FprA), Fdx, and estriol-bound CYP51 indicates heme iron reduction as a r

25 the ligand-free form and 4.3 min(-1) in the estriol-bound form, despite a thermodynamic barrier.

26 P51 is -375 mV, increasing to -225 mV in the estriol-bound form.

27 rosis have shown that the pregnancy hormone, estriol, can ameliorate disease and can cause an immune

28 furnishes 2-arylated estrone, estradiol, or estriol depending on the method used.

29 luding estrone (E(1)), estradiol (E(2)), and estriol (E(3)), fluctuate with life stage, suggesting sp

30 that in estrone (E(1)), estradiol (E(2)) and estriol (E(3)).

31 Estriol (E3), a pregnancy-specific estrogen, has therape

32 rogens [estrone (E1), 17beta-estradiol (E2), estriol (E3), and 17alpha-ethinylestradiol (EE2)] and tw

33 xpanded our testing to include estrone (E1), estriol (E3), progesterone, and dexamethasone.

34 Linearity for dansylated estriol, estrone, and estradiol was excellent over the e

35 phy is complete within 10 min for dansylated estriol, estrone, and estradiol.

36 ttle discriminatory ability as indicators of estriol, estrone, estradiol, or progesterone levels.

37 extraction and derivatization procedure for estriol from pregnancy urine samples.

38 olled 164 patients: 83 were allocated to the estriol group and 81 were allocated to the placebo group

39 nts did not differ substantially between the estriol group and the placebo group (eight [10%] of 82 p

40 Irregular menses were more common in the estriol group than in the placebo group (19 [23%] vs thr

41 relapses per year (95% CI 0.17-0.37) in the estriol group versus 0.37 relapses per year (0.25-0.53)

42 vacizumab group, 8.0 (IQR, 4.0-12.0) for the estriol group, 7.5 (IQR, 3.0-11.0) for the tranexamic ac

43 asured serum alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin (hCG), the free be

44 10 levels correlate with serum estradiol and estriol, implicating hormonal involvement in this alignm

45 clerosis patients with the pregnancy hormone estriol in an attempt to recapitulate the beneficial eff

46 eatment strategy of using pregnancy doses of estriol in multiple sclerosis has relevance to other aut

47 The hormone estriol increases during pregnancy and has been shown to

48 Estradiol and estriol induced alginate production in P. aeruginosa str

49 Estradiol and estriol induced mucoid conversion of P. aeruginosa in wo

50 decrease during pregnancy, when the hormone estriol is increased.

51 sults, a larger, placebo-controlled trial of estriol is warranted in women with relapsing remitting m

52 (r = 0.32) and strong associations with high estriol levels (odds ratio for highest compared with low

53 e performance of birth weight as a proxy for estriol levels was poor (area under the receiver operati

54 iation observed was between birth weight and estriol levels.

55 the effects of estradiol and its metabolite estriol on P. aeruginosa in vitro and in vivo and determ

56 Estriol plus glatiramer acetate met our criteria for red

57 posed to pregnancy hormones progesterone and estriol promote the establishment of maternal tolerance

58 -arm study of people with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was fav

59 ma concentrations of estradiol, unconjugated estriol, testosterone, progesterone, prolactin, sex horm

60 Further study of oral estriol therapy is warranted in Th1-mediated autoimmune

61 Here, the immunomodulatory effects of oral estriol therapy were assessed.

62 in the CNS of estrogen (17beta-estradiol or estriol)-treated mice.

63 Estriol treatment is anti-inflammatory and neuroprotecti

64 In a pilot trial, oral estriol treatment of relapsing remitting multiple sclero

65 We assessed whether estriol treatment reduces multiple sclerosis relapses in

66 When estriol treatment was reinstituted, enhancing lesions ag

67 When estriol treatment was stopped, enhancing lesions increas

68 observed in stimulated PBMC isolated during estriol treatment.

69 cal intranasal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis freq

70 Estriol was also effective but at doses below those prev

71 The P450 form is stabilized by estriol, which induces a type I spectral shift on bindin

72 n of diethyl carbamate-protected estrone and estriol with aryl iodides gives the 2-arylated analogues